Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Perturbation of biological processes with small molecule kinase inhibitors

Development of small-molecule inhibitors that target PI3Kβ

Small Molecules Targeting Phosphoinositide 3-Kinases

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Targeting cancer with small molecule kinase inhibitors

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Kinase Inhibition via Small Molecule‐Induced Intramolecular Protein Cross‐Linking

Controlling Kinase Activities by Selective Inhibition of Peptide Substrates

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Dynamics of Post-Translational Modification Inspires Drug Design in the Kinase Family

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Spatiotemporal control of kinases and the biomolecular tools to trace activity

Kinases in motion: impact of protein and small molecule interactions on kinase conformations

Impact of protein and small molecule interactions on kinase conformations

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches

A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors.

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics